Regeneron Pharmaceuticals (REGN) Earning Somewhat Positive Media Coverage, Analysis Shows

Media headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.8945295768668 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Regeneron Pharmaceuticals (NASDAQ REGN) traded up $11.61 during mid-day trading on Friday, reaching $373.47. The company’s stock had a trading volume of 1,799,404 shares, compared to its average volume of 954,248. The company has a market cap of $40,125.25, a PE ratio of 32.34, a PEG ratio of 1.47 and a beta of 1.54. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.13 EPS. equities analysts expect that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.

REGN has been the topic of several research reports. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Barclays downgraded Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Finally, Zacks Investment Research raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average target price of $467.84.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,352 shares of company stock valued at $2,037,772. Corporate insiders own 10.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals (REGN) Earning Somewhat Positive Media Coverage, Analysis Shows” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.com-unik.info/2017/12/03/regeneron-pharmaceuticals-regn-earning-somewhat-positive-media-coverage-analysis-shows.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit